Rohto Pharmaceutical Co.,Ltd.
Simbols: 4527.T
JPX
3200
JPYTirgus cena šodien
23.2296
P/E koeficients
0.8870
PEG koeficients
730.04B
MRK Cap
- 0.01%
DIV ienesīgums
Rohto Pharmaceutical Co.,Ltd. (4527-T) Finanšu pārskati
Bilance
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 79951 | 72791 | 52964 | ||||||||||||||||
balance-sheet.row.short-term-investments | 0 | 1008 | 661 | -1199 | ||||||||||||||||
balance-sheet.row.net-receivables | 0 | 60656 | 51682 | 47865 | ||||||||||||||||
balance-sheet.row.inventory | 0 | 41062 | 33527 | 27925 | ||||||||||||||||
balance-sheet.row.other-current-assets | 0 | 29547 | 24678 | 20975 | ||||||||||||||||
balance-sheet.row.total-current-assets | 0 | 190246 | 164306 | 133071 | ||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 66182 | 62839 | 49790 | ||||||||||||||||
balance-sheet.row.goodwill | 0 | 2564 | 2954 | 4014 | ||||||||||||||||
balance-sheet.row.intangible-assets | 0 | 6997 | 6338 | 3521 | ||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 9561 | 9292 | 7535 | ||||||||||||||||
balance-sheet.row.long-term-investments | 0 | 32629 | 27471 | 27425 | ||||||||||||||||
balance-sheet.row.tax-assets | 0 | 5371 | 5297 | 4606 | ||||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 5686 | 5419 | 3361 | ||||||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 119429 | 110318 | 92717 | ||||||||||||||||
balance-sheet.row.other-assets | 0 | 2 | 3 | 2 | ||||||||||||||||
balance-sheet.row.total-assets | 0 | 309677 | 274627 | 225790 | ||||||||||||||||
balance-sheet.row.account-payables | 0 | 16025 | 13660 | 9603 | ||||||||||||||||
balance-sheet.row.short-term-debt | 0 | 4177 | 8033 | 2312 | ||||||||||||||||
balance-sheet.row.tax-payables | 0 | 6230 | 3185 | 6138 | ||||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 7516 | 13350 | 5787 | ||||||||||||||||
Deferred Revenue Non Current | 0 | 3146 | 3387 | 5126 | ||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||||||||
balance-sheet.row.other-current-liab | 0 | 29368 | 27256 | 10008 | ||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 14439 | 19311 | 12708 | ||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 1184 | 1184 | 179 | ||||||||||||||||
balance-sheet.row.total-liab | 0 | 94601 | 90799 | 69179 | ||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.common-stock | 0 | 6504 | 6504 | 6504 | ||||||||||||||||
balance-sheet.row.retained-earnings | 0 | 184005 | 162195 | 145511 | ||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 18705 | 8735 | 3167 | ||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 354 | 851 | 725 | ||||||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 209568 | 178285 | 155907 | ||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 309677 | 274627 | 225790 | ||||||||||||||||
balance-sheet.row.minority-interest | 0 | 5508 | 5543 | 704 | ||||||||||||||||
balance-sheet.row.total-equity | 0 | 215076 | 183828 | 156611 | ||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||||||||||||||
Total Investments | 0 | 33637 | 28132 | 26226 | ||||||||||||||||
balance-sheet.row.total-debt | 0 | 11693 | 21383 | 8099 | ||||||||||||||||
balance-sheet.row.net-debt | 0 | -68258 | -51408 | -44865 |
Naudas plūsmas pārskats
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 34290 | 27953 | 23006 | ||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 7801 | 7673 | 6748 | ||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.change-in-working-capital | 0 | -11277 | 458 | 3402 | ||||||||||||||||
cash-flows.row.account-receivables | 0 | -7560 | -30 | 2464 | ||||||||||||||||
cash-flows.row.inventory | 0 | -6105 | -3061 | 3188 | ||||||||||||||||
cash-flows.row.account-payables | 0 | 1716 | 3323 | -2811 | ||||||||||||||||
cash-flows.row.other-working-capital | 0 | 672 | 226 | 561 | ||||||||||||||||
cash-flows.row.other-non-cash-items | 0 | 110 | -8834 | -13148 | ||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -9908 | -11328 | -10304 | ||||||||||||||||
cash-flows.row.acquisitions-net | 0 | -1582 | -1203 | -1516 | ||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | -5940 | -5615 | -2206 | ||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 2641 | 1963 | 4050 | ||||||||||||||||
cash-flows.row.other-investing-activites | 0 | 1613 | -223 | -261 | ||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -13176 | -16406 | -10237 | ||||||||||||||||
cash-flows.row.debt-repayment | 0 | -8761 | -3133 | -1880 | ||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.dividends-paid | 0 | -4676 | -3422 | -2965 | ||||||||||||||||
cash-flows.row.other-financing-activites | 0 | -2762 | 10025 | 2498 | ||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -16199 | 3470 | -2347 | ||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 5236 | 4335 | 96 | ||||||||||||||||
cash-flows.row.net-change-in-cash | 0 | 6786 | 18651 | 7589 | ||||||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 77691 | 70905 | 52254 | ||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 70905 | 52254 | 44665 | ||||||||||||||||
cash-flows.row.operating-cash-flow | 0 | 30924 | 27250 | 20008 | ||||||||||||||||
cash-flows.row.capital-expenditure | 0 | -9908 | -11328 | -10304 | ||||||||||||||||
cash-flows.row.free-cash-flow | 0 | 21016 | 15922 | 9704 |
Peļņas vai zaudējumu aprēķina rinda
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 238664 | 199646 | 181053 | ||||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 101243 | 83157 | 74326 | ||||||||||||||||
income-statement-row.row.gross-profit | 0 | 137421 | 116489 | 106727 | ||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.other-expenses | 0 | -63 | 246 | 260 | ||||||||||||||||
income-statement-row.row.operating-expenses | 0 | 103457 | 87135 | 83732 | ||||||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 204700 | 170292 | 158058 | ||||||||||||||||
income-statement-row.row.interest-income | 0 | 962 | 368 | 341 | ||||||||||||||||
income-statement-row.row.interest-expense | 0 | 247 | 248 | 145 | ||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | 751 | -240 | 1139 | ||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | -63 | 246 | 260 | ||||||||||||||||
income-statement-row.row.total-operating-expenses | 0 | 751 | -240 | 1139 | ||||||||||||||||
income-statement-row.row.interest-expense | 0 | 247 | 248 | 145 | ||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 7801 | 7673 | 6748 | ||||||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.operating-income | 0 | 33959 | 29349 | 22990 | ||||||||||||||||
income-statement-row.row.income-before-tax | 0 | 34290 | 27953 | 23006 | ||||||||||||||||
income-statement-row.row.income-tax-expense | 0 | 7860 | 6803 | 6236 | ||||||||||||||||
income-statement-row.row.net-income | 0 | 26377 | 21127 | 16743 |
Biežāk uzdotie jautājumi
Kas ir Rohto Pharmaceutical Co.,Ltd. (4527.T) kopējie aktīvi?
Rohto Pharmaceutical Co.,Ltd. (4527.T) kopējie aktīvi ir 309677000000.000.
Kādi ir uzņēmuma gada ieņēmumi?
Gada ieņēmumi ir N/A.
Kāda ir uzņēmuma peļņas norma?
Uzņēmuma peļņas norma ir 0.582.
Kāda ir uzņēmuma brīvā naudas plūsma?
Brīvā naudas plūsma ir 74.691.
Kāda ir uzņēmuma neto peļņas norma?
Neto peļņas norma ir 0.117.
Kādi ir uzņēmuma kopējie ieņēmumi?
Kopējie ieņēmumi ir 0.154.
Kāda ir Rohto Pharmaceutical Co.,Ltd. (4527.T) tīrā peļņa (tīrie ienākumi)?
Tīrā peļņa (tīrie ienākumi) ir 26377000000.000.
Kāds ir uzņēmuma kopējais parāds?
Kopējais parāds ir 11693000000.000.
Kāds ir pamatdarbības izdevumu skaits?
Darbības izdevumi ir 103457000000.000.
Kāds ir uzņēmuma skaidrās naudas rādītājs?
Uzņēmuma nauda ir 0.000.